Navigation Links
Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease

GCase levels in various tissues, including the brain, in mice genetically modified to produce the L444P form of the enzyme. In addition, liver and spleen weights were decreased as were plasma levels of chitin III and IgG, which are biomarkers related to Gaucher disease. The L444P is one of the most common mutations associated with Gaucher disease. Gaucher patients with two copies of this mutation typically have neurological symptoms in addition to the visceral symptoms seen in Type I Gaucher disease. About Gaucher Disease

Gaucher disease, the most commonly diagnosed lysosomal storage disorder, is caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system. Gaucher disease affects an estimated 8,000 to 10,000 people worldwide. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet med
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
(Date:9/15/2014)... 15, 2014 The Best Hospitals ... Report consists of seven hospitals using OnBase as their ... and Cleveland Clinic were ranked at the top of ... The rankings cover nearly 5,000 medical centers across the ... hospitals that scored highest in at least six of ...
(Date:9/15/2014)... Randy Dotinga HealthDay Reporter ... Patients prescribed cholesterol-lowering drugs are more likely to fill ... are cheaper generic brands, new research suggests. At ... brands include Crestor, Zocor and Lipitor. Generic statins are ... risk of heart problems due to clogged arteries. ...
(Date:9/15/2014)... Worth, FL (PRWEB) September 15, 2014 ... policy away from putting low-level offenders in jail and ... Treatment Group sees this shift as a positive change. ... of prescription drug and heroin abuse. According to an ... both parties are calling for a shift away from ...
(Date:9/15/2014)... By Dennis Thompson ... (HealthDay News) -- The severe respiratory virus believed to ... Western states has now spread to the Northeast, health ... Health confirmed on Friday more than a dozen cases ... especially for children with asthma. And on Saturday, ...
(Date:9/15/2014)... 15, 2014 Array Health ... technology, today announced that Independence Blue Cross ... southeastern Pennsylvania, has selected the Array Spectrum™ Private ... exchange marketplace for employers with more than 100 ... Spectrum™, Independence will offer employer groups a comprehensive ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:White House Shifts Policy on Drugs 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... East Hills, NY (Sept. 19, 2007) -- Each year ... critical part of their donation literally go down the ... collected annually, a majority (about two-thirds) of the four ... banks are replacing this valuable resource with much more ...
... Former Speaker of the,House and founder of the ... of conservative Republican lawmakers on Capitol Hill,today that while ... over the State Children,s Health Insurance Program (SCHIP) is ... insistent that Congress,not lose sight of the hundreds of ...
... Inc.,(OTC: ABOS) today announced Walter C. Ogier has resigned as ... of Directors. The Arbios Board,of Directors has appointed Shawn P. ... and CEO. The Company plans to,initiate a search for a ... Board of Directors has elected Amy,Factor as Vice Chairman. Ms. ...
... The majority of parents feel they play a ... according to researchers at the University of Michigan C.S. ... in the October issue of the Journal of Pediatrics, ... decisions made about their hospitalized childs medical care. Researchers ...
... million Americans who are living with cancer or have ... keeping their spirits intact: communication. In recognition of this, ... report by November 1, co-authored by a University of ... to good cancer care and deserves more research. , ...
... factor found at higher levels in these tumors, scientists say ... called nerve growth factor (NGF) may prove an effective target ... NGF is an essential component in the growth and differentiation ... in the Oct. 7 issue of the World Journal ...
Cached Medicine News:Health News:Critical blood shortages eased by new technology 2Health News:Critical blood shortages eased by new technology 3Health News:Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a 'Clean' SCHIP Six-Month Extension 2Health News:Arbios Announces Management Changes 2Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Communication in cancer world is key to survival 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: